Navigation Links
Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe
Date:12/11/2007

PRINCETON, N.J. and FOSTER CITY, Calif., Dec. 11 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY) and Gilead Sciences, Inc. (Nasdaq: GILD) today announced an agreement to commercialize ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe for the treatment of virologically suppressed adults with HIV-1 infection, subject to the product's approval by the European Commission. If approved, ATRIPLA would represent the first and only once-daily single tablet regimen for HIV-1 infection in the European Union. The companies expect the European Commission to issue its decision by the end of the year.

Under this agreement, Bristol-Myers Squibb and Gilead share responsibility for commercializing ATRIPLA throughout the European Union and certain other European countries. Gilead will record revenues from future net sales of ATRIPLA in most of the European countries, while Bristol-Myers Squibb will record revenues in most of the European countries at percentages relative to the contribution represented by its individual product.

Bristol-Myers Squibb recently concluded an agreement with Merck & Co., Inc. under which Merck granted Bristol-Myers Squibb rights to co-commercialize ATRIPLA with Gilead in all of the European Union and certain other European countries. Previously, Merck had the exclusive right to market any product containing efavirenz (a component of ATRIPLA) in all European countries other than the United Kingdom, Germany, France, Italy, Spain and
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Bristol-Myers Squibb, New Jersey Childrens Hospital Launch Center for Immune System Disorders & Infectious Diseases Including HIV/AIDS
2. Merck/Gilead Once-A-Day AIDS Pill Not Available in Most Places - AHF Urges Speed-Up of Registrations
3. PARIs eFlow Included in Gileads NDA Submission for Aztreonam Lysine for Inhalation
4. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
5. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
6. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
7. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
8. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
9. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
10. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
11. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Research and Markets has announced the addition ... report to their offering. Benefiting ... for medical expenses, the Chinese orthopedic instrument market demand ... CAGR of 19.2% during 2009-2013. Trauma products, spine products ... instruments in China , of which ...
(Date:8/29/2014)... Research and Markets has announced the addition ... Pharmaceutical Equipment Market in China, 2014-2018" report to ... Forecast of Pharmaceutical Equipment Market in China ... pharmaceutical equipment industry in the aspects of current ... performance of domestic major enterprises, as well as offers ...
(Date:8/29/2014)... 29, 2014  Unilife Corporation ("Unilife" or "Company") (NASDAQ: ... it intends to release its financial results for the ... 2014 after market trading ends on Tuesday, September 9, ... call for 4:30 p.m. U.S. EDT on Tuesday, September ... to review the Company,s financial results, commercial partnerships, and ...
Breaking Medicine Technology:China Orthopedic Instrument Industry Report, 2014-2017 2Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2
(Date:8/29/2014)... Denver, Colorado (PRWEB) August 29, 2014 ... Treatment. This is an absolutely unique method of curing ... The new program was created by Dr. Gary M. ... The health specialist started to become interested in alternative ... realized that classical remedies cannot be effective in all ...
(Date:8/29/2014)... 29, 2014 Dr. Mohebi’s lecture on ... talked about introducing these cutting edge techniques at their ... the FUE Research Committee has allowed him the ability ... is possible with modern technology. Dr. Mohebi stated, “We ... FUE devices that facilitate extraction and implantation of hair ...
(Date:8/29/2014)... reported by CNN.com in the article Prescription Drug Abuse: ... you need help for a prescription drug abuse problem can ... that if you simply try to find general help for ... the information that is available online. Although the information available ... possible to get help. The statistics from SAMSHA remind the ...
(Date:8/29/2014)... August 30, 2014 Market Research ... 2009-2019 is a professional and in-depth market survey ... report firstly reviews the basic information of Glass ... The report then explores global and China’s top ... capacity, Production value, and market share etc. , ...
(Date:8/29/2014)... Del Mar, CA (PRWEB) August 29, 2014 ... “oyasumi bra,” a bra developed by a Tokyo clothing store ... bed in the hopes of rectifying or diminishing their problem. ... has treated men with the problem. While many people only ... is actually a fairly common condition among men of all ...
Breaking Medicine News(10 mins):Health News:New Natural Multiple Sclerosis Treatment Review Reveals Gary M. Levin’s Unique Cure 2Health News:Parsa Mohebi M.D., Beverly Hills Hair Restoration Surgeon Gives Inspiring Lecture on Groundbreaking Techniques in Follicular Unit Extraction 2Health News:What to Know When Seeking Drug Addiction Help 2Health News:What to Know When Seeking Drug Addiction Help 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4Health News:New Bra Created for Men with Gynecomastia, But Will It Work? 2Health News:New Bra Created for Men with Gynecomastia, But Will It Work? 3
... in an extremely exciting phase right now. We are ... formed and are starting clinical trials in different areas," ... first-in-human study was just initiated for Parkinson,s disease patients ... NeuroNova. The drug, which is administered into the fluid-filled ...
... ST. PAUL, Minn., May 21 Three HealthEast ... agreed to pay the federal government a total ... tam") lawsuit alleging Medicare fraud involving a certain ... hospitals are the first hospitals to settle charges ...
... FRANCISCO -- Mayo Clinic researchers have found that bipolar ... as diabetes, depression, asthma or coronary artery disease. These ... claim costs. Specialty care costs (the costs of seeing ... for bipolar patients. Results of this review are being ...
... May 21 Elimination of funding for ... by the Senate Republican budget plan would end a ... rate of health care cost increases, improving quality of ... today.For the past two years the small "think tank" ...
... HMS today announced that it had been awarded contracts ... million lives to the company,s portfolio. HMS will be providing ... party recovery and cost avoidance -- to Citrus Health Care, ... (NY); Health First (NY); Health Plan of Michigan, Inc. (MI); ...
... (May 21, 2009) In comparing ultrasound with other medical ... review of published studies in the May/June issue of ... of ultrasound to provide an accurate diagnosis more cost ... the 1950s, ultrasound has been utilized mostly in hospital settings. ...
Cached Medicine News:Health News:Minnesota Hospitals Pay $2.28 Million to Settle Medicare Fraud Charges Involving Kyphoplasty 2Health News:Minnesota Hospitals Pay $2.28 Million to Settle Medicare Fraud Charges Involving Kyphoplasty 3Health News:Senate Republican Budget Would End Health Initiatives That Save Lives and Money 2Health News:Senate Republican Budget Would End Health Initiatives That Save Lives and Money 3Health News:Senate Republican Budget Would End Health Initiatives That Save Lives and Money 4
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: